Comparative analysis of zonisamide and topiramate use in treatment of pediatric epilepsy in real clinical practice: the results of a retrospective study and related clinical cases
https://doi.org/10.17650/2073-8803-2019-14-4-17-25
Abstract
Background. Comparative study of antiepileptic drugs allows to make the optimal choice in therapy.
The aim of the study: a comparative analysis of the administration of two similar by chemical structure antiepileptic drugs (zonisamide and topiramate) in the outpatient practice in epilepsy in children, taking into account the efficacy and tolerability.
Materials and methods. A retrospective analysis of outpatient charts of equal in number (n = 18) groups of patients with different forms of epilepsy treated with zonisamide and topiramate in monotherapy and in combined therapy was carried out.
Results. In general, no statistically significant difference in the efficacy of zonisamide and topiramate was obtained (p = 0.692). Efficacy in structural focal epilepsy was also comparable (absence of seizures 54.6 % and 45.5 %, respectively). With comparable efficacy, zonisamide was administered to patients much later in the antiepileptic drugs (Me = 5) than topiramate (Me = 3). Side effects on zonisamide were registered in 27.8 %, side effects on topiramate – in 38.9 % (p = 0.480). The difference in the effect of these drugs on cognitive functions was noted.
Conclusions. Zonisamide shows its effectiveness in different forms of epilepsy in children, despite the later appointment in practice. The drug is well tolerated and probably has less negative effect on children’s cognitive functions than topiramate.
Supporting agencies: This publication has been produced with the financial support of Eisai Co., Ltd.
About the Authors
O. A. Rakhmanina
Tumen State Medical University, Ministry of Health of Russia; Regional Treatment and Rehabilitation Center
Russian Federation
54 Odesskaya St., Tumen 625023, Russia; 11 Schorsa St., Tumen 625048, Russia
Russian Federation
54 Odesskaya St., Tumen 625023, Russia; 11 Schorsa St., Tumen 625048, Russia
E. V. Levitina
Tumen State Medical University, Ministry of Health of Russia
Russian Federation
54 Odesskaya St., Tumen 625023, Russia
Russian Federation
54 Odesskaya St., Tumen 625023, Russia
E. B. Khramova
Tumen State Medical University, Ministry of Health of Russia
Russian Federation
54 Odesskaya St., Tumen 625023, Russia
Russian Federation
54 Odesskaya St., Tumen 625023, Russia
O. L. Keln
Regional Clinical Hospital No. 1
Russian Federation
55 Kotovskogo St., Tumen 625023, Russia
Russian Federation
55 Kotovskogo St., Tumen 625023, Russia
V. A. Zmanovskaya
Children’s Psychoneurological Treatment and Rehabilitation Center “Hope”
Russian Federation
80 Khokhryakova St., Tumen 625000, Russia
Russian Federation
80 Khokhryakova St., Tumen 625000, Russia
References
1. Burd S.G., Mironov M.B., Gunchenko M.M., Sarzhina M.N. Perampanel in the treatment of refractory epilepsy in everyday clinical practice in adolescents. Epilepsia i paroksizmalnye sostoyaniya = Epilepsy and Paroxysmal Conditions 2016;8(4):84–90. (In Russ.) DOI: 10.17749/2077-8333.2016.8.4.084-090.
2. Voronkova K.V., Ermolenko N.A., Lebedeva D.I., Petrukhin A.S. Treatment of epilepsy in patients of “vulnerable” age: the adolescents and the elderly. Epilepsia i paroksizmalnye sostoyaniya = Epilepsy and Paroxysmal Conditions 2017;9(3):32–8. (In Russ.) DOI: 10.17749/2077-8333.2017.9.3.032-038.
3. Voronkova K.V., Nikitin A.E., Rudakova I.G. et al. Today’s choice of antiepileptic therapy: stages and recommendations. Epilepsia i paroksizmalnye sostoyaniya = Epilepsy and Paroxysmal Conditions 2018;10(2):74–81. (In Russ.) DOI: 10.17749/2077-8333.2018.10.2.074-081.
4. Guzeva V.I., Korostovtsev D.D., Fomina M.Yu. Evaluation of the effectiveness of Topamax (topiramate) in the treatment of various forms of epilepsy in children, adolescents and adults. Nervnye bolezni = Nervous Disease 2006;(2):17–23. (In Russ.)
5. Mukhin K.Yu., Pylaeva O.A. Application of zonisamide (Zonegran) in the treatment of epilepsy in adults and children (review of foreign literature and description of the case). Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2015;1(1):47–63. (In Russ.) DOI: 10.17650/2073-8803-2015-1-47-63.
6. Pylaeva O.A., Mukhin K.Yu. Use of zonisamide (zonegran) in the treatment of epilepsy: emphasis on monotherapy of focal seizures (review of foreign literature). Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2014;(2):42–9. (In Russ.)
7. Rudakova I.G. Zonegran. New in evidential pharmacotherapy of epilepsy: opportunities and expectations. Epilepsia i paroksizmalnye sostoyaniya = Epilepsy and Paroxysmal Conditions 2014;6(1):64–9. (In Russ.)
8. Rudakova I.G. Pharmacotherapy of epilepsy: administration of topiramate in starting and additional therapy. Zhurnal nevrologii i psikhiatrii = Journal of Neurology and Psychiatry 2012;112(6):58–64. (In Russ.)
9. Aldenkamp A., Besag F., Gobbi G. et al. Psychiatric and Behavioural Disorders in Children with Epilepsy (ILAE Task Force Report): Adverse cognitive and behavioural effects of antiepileptic drugs in children. Epileptic Disord 2016;18(Suppl 1):S55–67.
10. Aneja S., Sharma S. Newer anti-epileptic drugs. Indian Pediatr 2013;50(11):1033–40. DOI: 10.1007/s13312-013-0284-9.
11. Arroyo S., Dodson W.E., Privitera M.D. et al. For the EPMN-106/INT-28 study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 2005;112:214–22. DOI: 10.1111/j.1600-0404.2005.00485.
12. Baulac M., Brodie M.J., Patten A. et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2012;11(7):579–88. DOI: 10.1016/S1474-4422(12)70105-9.
13. Brodie M.J., Barry S.J., Bamagous G.A. et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012;78(20):1548–54. DOI: 10.1212/WNL.0b013e3182563b19.
14. Crepeau A.Z., Moseley B.D., Wirrell E.C. Specific safety and tolerability considerations in the use of anticonvulsant medications in children. Drug Healthc Patient Saf 2012;4:39–54.
15. Cross J.H., Auvin S., Patten A., Giorgi L. Safety and tolerability of zonisamide in paediatric patients with epilepsy. Eur J Paediatr Neurol 2014;18(6):747–58. DOI: 10.1016/j.ejpn.2014.07.005.
16. Gibbs J.W.I., Sombati S., DeLorenzo R.J., Coulter D.A. Cellular actions of topiramate: Blockade of kainateevoked inward currents in cultured hippocampal neurons. Epilepsia 2000;41(Suppl 1):S10–6. DOI: 10.1111/j.1528-1157.2000.tb02164.x.
17. Gilliam F.G., Veloso F., Bomhof M.A. et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003;60:196–202. DOI: 10.1212/01.wnl.0000048200.12663.bc.
18. Guerrini R., Rosati A., Segieth J. et al. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia 2013;54(8):1473–80. DOI: 10.1111/epi.12233.
19. Guerrini R., Rosati A., Bradshaw K., Giorgi L. Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an openlabel extension study of a phase III, randomized, double-blind placebocontrolled trial. Epilepsia 2014;5:568–578. DOI: 10.1111/epi.12548.
20. Lagae L., Meshram C., Giorgi L., Patten A. Effects of adjunctive zonisamide treatment on weight and body mass index in children with partial epilepsy. Acta Neurol Scand 2015;131(5):341–6. DOI: 10.1111/ane.12373.
21. Langtry H.D., Gillis J.C., Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997;54(5):752–73. DOI: 10.2165/00003495-199754050-00009.
22. Privitera M.D., Brodie M.J., Mattson R.H. et al. For the EPMN 105 Study Group. Topiramate, carbamazepine and valproate monotherapy: Double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165–75. DOI: 10.1034/j.1600-0404.2003.00093.
23. Shinnar S., Pellok J.M., Conry J.A. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Ped Neurol 2009;13(1):3–9. DOI: 10.1016/j.ejpn.2008.01.004.
24. Tassinari C.A., Michelucci R., Chauvel P. et al. Double-blind, placebocontrolled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763–8. DOI: 10.1111/j.1528-1157.1996.tb00649.x.
25. Wallander K.M., Ohman I., Dahlin M. Zonisamide: pharmacokinetics, efficacy, and adverse events in children with epilepsy. Neuropediatrics 2014;45(6):362–70. DOI: 10.1055/s-0034-1387815.
26. Wandschneider B., Burdett J., Townsend L. et al. Effect of topiramate and zonisamide on fMRI cognitive networks. Neurology 2017;88(12):1165–71.
Review
For citations:
Rakhmanina O.A., Levitina E.V., Khramova E.B., Keln O.L., Zmanovskaya V.A. Comparative analysis of zonisamide and topiramate use in treatment of pediatric epilepsy in real clinical practice: the results of a retrospective study and related clinical cases. Russian Journal of Child Neurology. 2019;14(4):17-25. (In Russ.) https://doi.org/10.17650/2073-8803-2019-14-4-17-25
Views:
990
Email this article 